Filing Details

Accession Number:
0001415889-22-010879
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-10-28 16:15:27
Reporting Period:
2022-10-26
Accepted Time:
2022-10-28 16:15:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479419 Kala Pharmaceuticals Inc. KALA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1298079 K Romulus Brazzell C/O Kala Pharmaceuticals, Inc.
1167 Massachusetts Avenue
Arlington MA 02476
See Remarks No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-10-26 261 $6.51 5,809 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.59, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  3. Includes 367 unvested RSUs and 365 shares acquired under the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan on June 30, 2022.
  4. The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022.